Sign up Australia
Proactive Investors - Run By Investors For Investors

Neuren Pharmaceuticals granted ASX trading halt pending trial update

The halt will remain in place until Wednesday 22nd March 2017.
no_picture_pai.jpg
Neuren to update on trial

Neuren Pharmaceuticals (ASX:NEU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Neuren requested the halt pending details regarding Neuren’s Phase 2 clinical trial of trofinetide in Rett syndrome.

The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.





Register here to be notified of future NEU Company articles
View full NEU profile View Profile

Neuren Pharmaceuticals Timeline

Related Articles

mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
genomics.jpg
October 05 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use